Medline (NASDAQ:MDLN) Major Shareholder Private Ltd Gic Sells 2,570,999 Shares of Stock

Medline (NASDAQ:MDLN) major shareholder Private Ltd Gic sold 2,570,999 shares of the stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $35.35, for a total transaction of $90,884,814.65. Following the completion of the transaction, the insider owned 20,231,483 shares of the company’s stock, valued at approximately $715,182,924.05. This represents a 11.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Private Ltd Gic also recently made the following trade(s):

• On Tuesday, October 6th, Private Ltd Gic sold 7,183,013 shares of Medline stock. The shares were sold at an average price of $35.05, for a total transaction of $251,764,605.65.
• On Tuesday, October 6th, Private Ltd Gic sold 2,088,987 shares of Medline stock. The shares were sold at an average price of $35.05, for a total transaction of $73,218,994.35.
• On Monday, October 5th, Private Ltd Gic sold 1,688,690 shares of Medline stock. The shares were sold at an average price of $35.78, for a total value of $60,421,328.20.
• On Friday, October 2nd, Private Ltd Gic sold 7,146,941 shares of Medline stock. The stock was sold at an average price of $34.33, for a total value of $245,354,484.53.
• On Friday, August 14th, Private Ltd Gic sold 100,000 shares of Medline stock. The stock was sold at an average price of $35.80, for a total transaction of $3,580,000.00.
• On Thursday, August 13th, Private Ltd Gic sold 1,500,000 shares of Medline stock. The stock was sold at an average price of $35.80, for a total transaction of $53,700,000.00.
• On Friday, August 7th, Private Ltd Gic sold 590,284 shares of Medline stock. The shares were sold at an average price of $35.58, for a total value of $21,002,304.72.
• On Thursday, August 6th, Private Ltd Gic sold 271,994 shares of Medline stock. The shares were sold at an average price of $35.33, for a total value of $9,609,548.02.
• On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total transaction of $70,367,600.80.

Medline Price Performance

Shares of MDLN stock opened at $35.45 on Thursday. Medline has a 1 year low of $31.49 and a 1 year high of $50.88. The firm’s 50 day moving average is $35.02 and its 200-day moving average is $38.49. The firm has a market capitalization of $46.61 billion and a price-to-earnings ratio of 44.87. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66.

Medline (NASDAQ:MDLN) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, beating analysts’ consensus estimates of $0.32 by $0.18. The company had revenue of $7.68 billion during the quarter. Sell-side analysts forecast that Medline will post 1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Medline

A number of hedge funds and other institutional investors have recently made changes to their positions in MDLN. Versant Capital Management Inc raised its stake in Medline by 1,864.5% during the 3rd quarter. Versant Capital Management Inc now owns 2,102 shares of the company’s stock worth $73,000 after buying an additional 1,995 shares during the period. Envestnet Portfolio Solutions Inc. grew its stake in Medline by 20.4% in the second quarter. Envestnet Portfolio Solutions Inc. now owns 12,705 shares of the company’s stock valued at $501,000 after acquiring an additional 2,149 shares during the period. Andra AP fonden bought a new stake in shares of Medline in the second quarter worth about $3,180,000. Core Capital Management & Research inc. bought a new stake in shares of Medline in the second quarter worth about $96,000. Finally, Tidal Investments LLC acquired a new stake in shares of Medline during the second quarter worth about $334,000.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Neutral Sentiment: Medline will release its third-quarter 2026 results before the market opens on November 4, followed by a conference call. The report should provide updates on demand, margins, product-quality issues and the company’s outlook. Medline third-quarter 2026 results announcement
• Negative Sentiment: Major shareholder Private Ltd GIC reported several large sales, including 2.57 million shares on October 2, 1.69 million on October 5 and 2.09 million on October 6. The transactions totaled roughly $224.5 million and materially reduced its ownership. The repeated selling may pressure MDLN by increasing share supply and signaling weaker shareholder conviction, although no reason was provided. SEC ownership filing
• Negative Sentiment: Several law firms, including Bleichmar Fonti & Auld, Pomerantz, Kaplan Fox and Kirby McInerney, announced investigations into Medline’s disclosures following a sharp stock decline. The notices allege potential securities-law violations related to manufacturing and product-quality statements; they do not establish wrongdoing, but raise risks of litigation costs, regulatory scrutiny and reputational damage. BFA Law Medline investor reminder
• Negative Sentiment: Product-quality concerns remain the main fundamental overhang. Investors may be concerned about possible recalls, remediation expenses, operational disruptions and effects on customer relationships until Medline provides more clarity in its upcoming results.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. William Blair restated an “outperform” rating on shares of Medline in a research report on Wednesday, September 23rd. Citigroup upgraded shares of Medline to a “strong-buy” rating in a research report on Wednesday, August 5th. Royal Bank Of Canada dropped their price target on shares of Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. UBS Group cut their price objective on shares of Medline from $45.00 to $43.00 and set a “buy” rating on the stock in a report on Friday, September 25th. Finally, Weiss Ratings raised shares of Medline from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $46.88.

About Medline

Medline Industries, Inc is a healthcare company that manufactures and distributes medical supplies, clinical products and equipment to hospitals, health systems, physician practices, long-term care facilities, surgery centers and other healthcare providers. Its offerings are designed to support patient care, surgical procedures, infection prevention and healthcare facility operations.

The company’s product portfolio includes surgical instruments and supplies, exam gloves and protective apparel, wound care products, patient-care items, respiratory and monitoring equipment, laboratory supplies, durable medical equipment and products for environmental and facility management.